STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug joins fight against tough head and neck cancers
Disease control Recruiting nowThis early-stage study is testing whether adding a new oral drug called ipatasertib to the standard treatment of chemotherapy plus radiation is safe and more effective for people with locally advanced head and neck cancer. The main goal is to find the safest and most effective do…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug duo aims to outsmart tough cancers that resist standard treatment
Disease control Recruiting nowThis study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Genetic test may guide chemo choice for head and neck cancer patients
Disease control Recruiting nowThis study is for people who have had surgery for stage III-IVA head and neck cancer. It tests whether adding the chemotherapy drug cisplatin to standard radiation treatment is better at preventing the cancer from coming back than radiation alone. The study also uses a genetic te…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New drug aims to shield cancer patients from painful mouth sores
Symptom relief Recruiting nowThis study is testing if adding an investigational drug called BMX-001 to standard symptom care can better prevent severe mouth sores in people receiving combined chemotherapy and radiation for head and neck cancer. About 98 participants will be randomly assigned to receive eithe…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Mar 16, 2026 15:26 UTC
-
Scientists probe why cancer patients skip crucial throat exercises
Knowledge-focused Recruiting nowThis study aims to understand why some head and neck cancer patients follow, and others skip, prescribed swallowing exercises after radiation therapy. Researchers will collect blood samples and ask patients to fill out questionnaires to see if factors like mood, pain, immune syst…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
New scan aims to spot hidden damage from cancer radiation
Knowledge-focused Recruiting nowThis study is testing whether a new type of PET/CT scan can better detect damage to neck blood vessels caused by radiation therapy for head and neck cancers. Researchers will compare the new scan to the standard scan in about 20 patients before and after their radiation treatment…
Matched conditions: STAGE III HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC